Please use this identifier to cite or link to this item: http://hdl.handle.net/2440/52128
Citations
Scopus Web of Science® Altmetric
?
?
Full metadata record
DC FieldValueLanguage
dc.contributor.authorHarmatz, P.en
dc.contributor.authorGiugliani, R.en
dc.contributor.authorSchwartz, I.en
dc.contributor.authorGuffon, N.en
dc.contributor.authorTeles, E.en
dc.contributor.authorMiranda, C.en
dc.contributor.authorWraith, J.en
dc.contributor.authorBeck, M.en
dc.contributor.authorArash, L.en
dc.contributor.authorScarpa, M.en
dc.contributor.authorKetteridge, D.en
dc.contributor.authorHopwood, J.en
dc.contributor.authorPlecko, B.en
dc.contributor.authorSteiner, R.en
dc.contributor.authorWhitley, C.en
dc.contributor.authorKaplan, P.en
dc.contributor.authorYu, Z.en
dc.contributor.authorSwiedler, S.en
dc.contributor.authorDecker, C.en
dc.date.issued2008en
dc.identifier.citationMolecular Genetics and Metabolism, 2008; 94(4):469-475en
dc.identifier.issn1096-7192en
dc.identifier.issn1096-7206en
dc.identifier.urihttp://hdl.handle.net/2440/52128-
dc.descriptionCopyright © 2008 Elsevier Inc. All rights reserved.en
dc.description.abstractUNLABELLED: The objective of this study was to evaluate the long-term clinical benefits and safety of recombinant human arylsulfatase B (rhASB) treatment of mucopolysaccharidosis type VI (MPS VI: Maroteaux-Lamy syndrome), a lysosomal storage disease. Fifty-six patients derived from 3 clinical studies were followed in open-label extension studies for a total period of 97-260 Weeks. All patients received weekly infusions of rhASB at 1 mg/kg. Efficacy was evaluated by (1) distance walked in a 12-minute walk test (12MWT) or 6-minute walk test (6MWT), (2) stairs climbed in the 3-minute stair climb (3MSC), and (3) reduction in urinary glycosaminoglycans (GAG). Safety was evaluated by compliance, adverse event (AE) reporting and adherence to treatment. RESULTS: A significant reduction in urinary GAG (71-79%) was sustained. For the 12MWT, subjects in Phase 2 showed improvement of 255+/-191 m (mean+/-SD) at Week 144; those in Phase 3 Extension demonstrated improvement from study baseline of 183+/-26 m (mean+/- SE) in the rhASB/rhASB group at Week 96 and from treatment baseline (Week 24) of 117+/-25 m in the placebo/rhASB group. The Phase 1/2 6MWT and the 3MSC from Phase 2 and 3 also showed sustained improvements through the final study measurements. Compliance was 98% overall. Only 560 of 4121 reported AEs (14%) were related to treatment with only 10 of 560 (2%) described as severe. CONCLUSION: rhASB treatment up to 5 years results in sustained improvements in endurance and has an acceptable safety profile.en
dc.description.statementofresponsibilityPaul Harmatz, Roberto Giugliani, Ida Vanessa D. Schwartz, Nathalie Guffon, Elisa Leão Teles, M. Clara Sá Miranda, J. Edmond Wraith, Michael Beck, Laila Arash, Maurizio Scarpa, David Ketteridge, John J. Hopwood, Barbara Plecko, Robert Steiner, Chester B. Whitley, Paige Kaplan, Zi-Fan Yu, Stuart J. Swiedler, Celeste Decker and for the MPS VI Study Groupen
dc.description.urihttp://www.elsevier.com/wps/find/journaldescription.cws_home/622920/description#descriptionen
dc.language.isoenen
dc.publisherAcademic Press Inc Elsevier Scienceen
dc.subjectMPS VI Study Group; Humans; Mucopolysaccharidosis VI; N-Acetylgalactosamine-4-Sulfatase; Glycosaminoglycans; Recombinant Proteins; Treatment Outcome; Walking; Follow-Up Studies; Motor Activity; Adolescent; Adult; Child; Child, Preschool; Female; Maleen
dc.titleLong-term follow-up of endurance and safety outcomes during enzyme replacement therapy for mucopolysaccharidosis VI: Final results of three clinical studies of recombinant human N-acetylgalactosamine 4-sulfataseen
dc.typeJournal articleen
dc.identifier.rmid0020081638en
dc.identifier.doi10.1016/j.ymgme.2008.04.001en
dc.identifier.pubid42654-
pubs.library.collectionPaediatrics publicationsen
pubs.verification-statusVerifieden
pubs.publication-statusPublisheden
Appears in Collections:Paediatrics publications

Files in This Item:
There are no files associated with this item.


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.